A Personalised Approach to Treating Parkinson’s: Should We Remove or Replenish Alpha-Synuclein?

Understanding Alpha-Synuclein’s Role in Parkinson’s Disease Parkinson’s disease is a complex condition affecting movement and brain function. One of the main culprits is a protein called alpha-synuclein (α-Syn), which can behave in different ways. Scientists have long believed that too much of this protein, or its clumped-up forms, causes problems in the brain. Many treatments have focused on reducing its levels or clearing these clumps. However, new research suggests that some people with Parkinson’s may actually need more of the normal version of this protein instead of less. The Two Sides of Alpha-Synuclein: Too Much or Too Little? Scientists describe alpha-synuclein’s effects in two ways: The “Gain-of-Function” Problem – This happens when too much of the protein builds up, forming toxic clumps known as Lewy bodies. These can damage brain cells and lead to Parkinson’s symptoms. People with certain genetic mutations or excessive production of alpha-synuclein are particularly at risk. The “Loss-of-Function” Problem – This theory suggests that not having enough properly functioning alpha-synuclein could also be harmful. The normal version of this protein plays an important role in keeping brain cells healthy, helping with communication between nerve cells and regulating dopamine levels. If too much alpha-synuclein is removed, it may lead to other problems. Why One-Size-Fits-All Treatments Might Not Work Current therapies aimed at reducing alpha-synuclein have shown mixed results. Some early drug trials that targeted the protein did not succeed, possibly because they were used on the wrong patients. New evidence suggests that Parkinson’s isn’t the same for everyone—some people might benefit from reducing alpha-synuclein levels, while others may need treatments that restore it. To develop better treatments, doctors and researchers need to personalise therapies based on each patient’s unique condition. This could mean: Reducing alpha-synuclein in people who produce too much or have harmful genetic mutations. Replacing alpha-synuclein in those who have lost too much of the healthy form of the protein. Targeting both issues in cases where both excessive and deficient alpha-synuclein contribute to the disease. The Future of Parkinson’s Treatments Since Parkinson’s is driven by multiple factors—not just alpha-synuclein—treatments will likely need to be multi-faceted. Future approaches may involve: Clearing toxic alpha-synuclein clumps without affecting healthy levels. Restoring normal alpha-synuclein in people who need it. Targeting other related issues, such as inflammation, mitochondrial damage, and metabolism changes. Conclusion Parkinson’s disease is not the same for everyone, and neither should its treatment be. Instead of a universal approach, a customised treatment strategy based on a person’s specific genetic and biochemical makeup could be the key to better outcomes. Scientists are now working towards identifying which patients need which type of treatment, paving the way for a more personalised and effective approach to fighting Parkinson’s.